Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in NF1-Associated Cutaneous Neurofibromas

Article summary

Pasithea Therapeutics has received FDA clearance for its Investigational New Drug (IND) application to begin clinical development of PAS-004 for the treatment of NF1-associated cutaneous neurofibromas.